Etanercept


Article Author:
Adrianne Pan


Article Editor:
Valerie Gerriets


Editors In Chief:
David Wood
Andrew Wilt
Hajira Basit


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
10/18/2019 1:06:41 AM

Indications

Etanercept is a biologic TNF inhibitor commonly used to control ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. Etanercept is a soluble receptor that binds both TNF-alpha and TNF-beta to inhibit the inflammatory response in joints and skin that is characteristic of these autoimmune disorders. The drug can be used as a monotherapy or taken with other immunosuppressants, such as methotrexate. 

FDA approved uses for etanercept[1][2][3][4][5][4][3][2][1]:

  • Ankylosing spondylitis
  • Juvenile idiopathic arthritis (2 years or older)
  • Plaque psoriasis (4 years or older)
  • Psoriatic arthritis
  • Rheumatoid arthritis

Off-label uses (not FDA approved):

  • Acute graft-versus-host disease (combined with methylprednisolone)
  • Behcet disease
  • Hidradenitis suppurativa 
  • Kawasaki disease 
  • Pemphigus vulgaris 
  • Pustular psoriasis 
  • Pyoderma gangrenosum 
  • Scleroderma/systemic sclerosis 
  • Still disease 

Mechanism of Action

Etanercept is a biologic tumor necrosis factor (TNF) inhibitor; the drug acts as a soluble TNF receptor and binds TNF-alpha and TNF-beta.[6] TNF is a cytokine that can bind to TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2) and is involved in inflammation and the immune response.[7] When TNF binds to TNFR1 or TNFR2, it activates important inflammatory pathways, such as NFkB and MAPK. The structure of Etanercept consists of two p75 TNF receptors fused to the Fc portion of human IgG.[6] Etanercept works by blocking the effects of TNF-alpha, a pro-inflammatory cytokine that becomes elevated in psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.

Administration

Etanercept administration is via subcutaneous injection, usually on the thigh, lower abdomen, or upper arm. If given on the abdomen, the injection should not be within the 2-inch area around the navel. Injections should be administered at least 1 inch away from previous injection sites. The medication comes in a pre-filled syringe, automatic injection device, or multiple-dose vial. After the initial injection of Etanercept at the doctor’s office, the patient can self-inject at home.[8]

For the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, 50 mg of etanercept is injected once a week. For psoriasis, the dosage is 50 mg twice weekly for three months, followed by 50 mg once weekly. Children with juvenile idiopathic arthritis are administered 0.8 mg/kg once a week, up to 50 mg.

Adverse Effects

The most common adverse effects include[1]:

  • Infection (viral, bacterial, and fungal – mostly upper respiratory tract infections)
  • Injection site reaction (erythema, itching, pain, swelling, bleeding, bruising)

Rare adverse effects include (in alphabetical order):

  • Blood and lymph disorders: aplastic anemia, leukopenia, myelodysplastic syndrome, neutropenia, pancytopenia, thrombocytopenia[9]
  • Cancers: lymphoma [10], skin cancers
  • Cardiopulmonary problems: congestive heart failure, interstitial lung disease[11]
  • Gastrointestinal and liver problems: autoimmune hepatitis,[12] diarrhea,[13] elevated transaminases,[14] inflammatory bowel disease,[15] nausea[16] 
  • Immune and inflammatory conditions:  angioedema,[17] hypersensitivity reaction,[18] lupus-like syndrome,[11] non-neutralizing anti-Etanercept antibodies,[1] pyrexia,[16] sarcoidosis, uveitis, vasculitis
  • Infections: aspergillosis,[19] candidiasis,[19] coccidioidomycosis, cryptococcus,[19] herpes zoster, histoplasmosis,[19] legionella pneumonia,[20] listeriosis,[19] nocardiosis,[19] pneumocystis pneumonia, reactivation of Hepatitis B or TB,[21] salmonella infection,[19] septic arthritis 
  • Nervous system disorders: headache.[5] multiple sclerosis, optic neuritis, paresthesias, seizures, transverse myelitis
  • Skin disorders: cutaneous lupus erythematosus,[22] erythema multiforme,[22] new or worsening psoriasis, rash, Stevens-Johnson syndrome,[22] toxic epidermal necrolysis,[22] urticaria

US boxed warnings

Infections, including tuberculosis:

Patients using etanercept have an increased risk of acquiring serious and/or fatal infections, including the development of active tuberculosis or reactivation of latent tuberculosis. There are reports of various bacterial, viral, and fungal infections, including invasive fungal (aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and opportunistic infections (legionellosis, listeriosis). 

Infections were more common in patients that received adjunct immunosuppressive medications, such as methotrexate or corticosteroids. Medical providers should exercise caution when prescribing etanercept to patients at higher risk for infections, including elderly patients, immunocompromised patients, patients with a history of recurrent/chronic/opportunistic infections, and patients exposed to tuberculosis or endemic mycoses. Physicians should consider empiric antifungal therapy for patients living in or traveling to endemic areas with an increased risk of invasive fungal infections.

Malignancies:

Reports exist of malignancies in patients receiving etanercept, especially in children and adolescents. Lymphomas were most commonly reported, followed by melanoma and other skin cancers. Though the connection between etanercept and malignancies is not fully understood, clinical trials and case reports showed an increased rate of lymphoma and other malignancies in patients on etanercept compared to the general population. However, it is worth noting that rheumatoid arthritis alone has associations with increased rates of lymphoma and leukemia.

Contraindications

Etanercept contraindications include patients with sepsis. Patients should not start etanercept during active bacterial infections, including tuberculosis (active or latent), active herpes zoster infection, active or chronic untreated Hepatitis B or C infection, or active invasive fungal infections.[23] Patients should not use etanercept if they have a hypersensitivity reaction to the medication ingredients.

Monitoring

Before starting etanercept, patients should receive screening for any infections, including latent tuberculosis or hepatitis B. Patients on etanercept require monitoring for signs of infection and reactivation or development of tuberculosis and hepatitis B.[24] If a severe infection or sepsis develops during etanercept treatment, discontinue treatment. Also, patients should have monitoring for signs or symptoms of hypersensitivity reactions, malignancy, or lupus-like syndrome. Patients with a history of heart failure also require monitoring during etanercept treatment.[25]

Toxicity

There have not been any dose-limiting toxicities observed during clinical trials, in vivo, and in vitro studies. However, the long-term toxicity of etanercept treatment is unknown.

Enhancing Healthcare Team Outcomes

Etanercept is one of several different options for the treatment of plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. The medical providers should weigh the risks and benefits of selecting etanercept as a treatment, such as drug cost, effectiveness, method of administration, and adverse effects. Because it is a biologic, etanercept usage comes with some serious side effects such as infections, malignancies, and autoimmune conditions.

An interprofessional team of physicians, nurses, and pharmacists must work together to ensure the safety and wellbeing of the patient. When deciding to treat with etanercept, physicians should know the treatment guidelines, which include monitoring the patient for signs of heart failure, tuberculosis, hepatitis B, and other infections before and during treatment. Clinicians and nurses will instruct the patient or the patient’s relative on how to properly give etanercept injections at home. Physicians and pharmacists must ensure that the patient is receiving the proper medication and dosage and that the patient receives on drug interactions and adverse effects. Nursing should keep the team informed regarding the appearance of these adverse reactions, as well as monitoring the success/failure of therapy. Also, biosimilars of etanercept have been emerging on the market, so healthcare providers need to be kept abreast regarding the different options that they have for treatment.[26][27] Without proper management, the quality of life in patients with these diseases is low. An interprofessional healthcare team can help achieve the best possible outcomes with minimal adverse events. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Etanercept - Questions

Take a quiz of the questions on this article.

Take Quiz
A 62-year-old female with rheumatoid arthritis has enrolled in a clinical study to assess the effectiveness of several medications. Which of the following inhibits tumor necrosis factor by binding to its receptor?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 16-year-old male patient presents with itchy, painful, raised, red patches of skin covered with silvery-white scales on his knees and elbows. The physician wants to prescribe Etanercept, a biologic tumor necrosis factor (TNF) inhibitor treatment. The patient must complete a screening test which involves injecting a small amount of fluid (containing antigens) just below the skin before starting treatment. Why is this test necessary?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old male patient with rheumatoid arthritis has had unsatisfactory treatment results from nonsteroidal anti-inflammatory drugs (NSAID) and suffered significant gastrointestinal side effects from their use. His provider decides to instead prescribe a soluble tumor necrosis factor (TNF) inhibitor that is injected subcutaneously once a week. Which of the following is a common side effect of this new treatment?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 17-year-old patient presents to the clinic with severe, chronic spinal pain for the last three months. An x-ray reveals new bony spurs in the spine and sacroiliac joint involvement. A blood test is positive for HLA-B27. The clinician prescribes a medication that is a soluble tumor necrosis factor (TNF) inhibitor. Which of the following best describes the mechanism of action of this drug?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 34-year-old female presents with wrist and metacarpophalangeal joint pain and stiffness that is worse in the morning and improves with use. She denies any weight changes, fever, and rash. She has no other medical conditions and does not take any medications. On examination, the right wrist is mildly tender but there is no gross swelling or redness. Appropriate labs are sent and the results are pending. Which of the following medications is most likely to be effective in controlling the progression of the patient's condition?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 10-year-old female presents to the clinic with stiff, painful, swollen knees. She is unable to run or walk for longer than a few minutes. Non-steroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying antirheumatic drugs (DMARDs) have been unsuccessful in treating her symptoms. Her clinician decides to prescribe an agent that is a soluble tumor necrosis factor (TNF) receptor fused to IgG. Which of the following medications is prescribed?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Etanercept - References

References

Davis JC Jr,Van Der Heijde D,Braun J,Dougados M,Cush J,Clegg DO,Kivitz A,Fleischmann R,Inman R,Tsuji W, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and rheumatism. 2003 Nov;     [PubMed]
Lovell DJ,Giannini EH,Reiff A,Cawkwell GD,Silverman ED,Nocton JJ,Stein LD,Gedalia A,Ilowite NT,Wallace CA,Whitmore J,Finck BK, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. The New England journal of medicine. 2000 Mar 16;     [PubMed]
Lovell DJ,Giannini EH,Reiff A,Jones OY,Schneider R,Olson JC,Stein LD,Gedalia A,Ilowite NT,Wallace CA,Lange M,Finck BK,Burge DJ, Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and rheumatism. 2003 Jan;     [PubMed]
Papp KA,Tyring S,Lahfa M,Prinz J,Griffiths CE,Nakanishi AM,Zitnik R,van de Kerkhof PC,Melvin L, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. The British journal of dermatology. 2005 Jun;     [PubMed]
Mease PJ,Kivitz AJ,Burch FX,Siegel EL,Cohen SB,Ory P,Salonen D,Rubenstein J,Sharp JT,Tsuji W, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis and rheumatism. 2004 Jul;     [PubMed]
Moreland LW,Schiff MH,Baumgartner SW,Tindall EA,Fleischmann RM,Bulpitt KJ,Weaver AL,Keystone EC,Furst DE,Mease PJ,Ruderman EM,Horwitz DA,Arkfeld DG,Garrison L,Burge DJ,Blosch CM,Lange ML,McDonnell ND,Weinblatt ME, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of internal medicine. 1999 Mar 16;     [PubMed]
Tracey D,Klareskog L,Sasso EH,Salfeld JG,Tak PP, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology     [PubMed]
Mocci G,Marzo M,Papa A,Armuzzi A,Guidi L, Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. Journal of Crohn's     [PubMed]
van den Bemt BJF,Gettings L,Domańska B,Bruggraber R,Mountian I,Kristensen LE, A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug delivery. 2019 Dec;     [PubMed]
van der Heijde D,Da Silva JC,Dougados M,Geher P,van der Horst-Bruinsma I,Juanola X,Olivieri I,Raeman F,Settas L,Sieper J,Szechinski J,Walker D,Boussuge MP,Wajdula JS,Paolozzi L,Fatenejad S, Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Annals of the rheumatic diseases. 2006 Dec;     [PubMed]
Feltelius N,Fored CM,Blomqvist P,Bertilsson L,Geborek P,Jacobsson LT,Lindblad S,Lysholm J,Rantapää-Dahlqvist S,Saxne T,Klareskog L, Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Annals of the rheumatic diseases. 2005 Feb;     [PubMed]
Brown SL,Greene MH,Gershon SK,Edwards ET,Braun MM, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis and rheumatism. 2002 Dec;     [PubMed]
Ramos-Casals M,Brito-Zerón P,Muñoz S,Soria N,Galiana D,Bertolaccini L,Cuadrado MJ,Khamashta MA, Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007 Jul;     [PubMed]
O'Toole A,Lucci M,Korzenik J, Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA. Digestive diseases and sciences. 2016 Jun;     [PubMed]
French JB,Bonacini M,Ghabril M,Foureau D,Bonkovsky HL, Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug safety. 2016 Mar;     [PubMed]
Puxeddu I,Caltran E,Rocchi V,Del Corso I,Tavoni A,Migliorini P, Hypersensitivity reactions during treatment with biological agents. Clinical and experimental rheumatology. 2016 Jan-Feb;     [PubMed]
Kerbleski JF,Gottlieb AB, Dermatological complications and safety of anti-TNF treatments. Gut. 2009 Aug;     [PubMed]
Sendur OF,Turan Y,Berkit IK,Tastaban E, Angio-oedema in a patient treated with etanercept for rheumatoid arthritis. Basic     [PubMed]
Wallis RS,Broder MS,Wong JY,Hanson ME,Beenhouwer DO, Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 May 1;     [PubMed]
Lanternier F,Tubach F,Ravaud P,Salmon D,Dellamonica P,Bretagne S,Couret M,Bouvard B,Debandt M,Gueit I,Gendre JP,Leone J,Nicolas N,Che D,Mariette X,Lortholary O, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest. 2013 Sep;     [PubMed]
Akhlaghi S,Sahebari M,Mahmoodi M,Yaseri M,Mansournia MA,Rafatpanah H,Zeraati H, Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. Therapeutics and clinical risk management. 2018;     [PubMed]
Cantini F,Niccoli L,Goletti D, Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. The Journal of rheumatology. Supplement. 2014 May;     [PubMed]
Singh JA,Saag KG,Bridges SL Jr,Akl EA,Bannuru RR,Sullivan MC,Vaysbrot E,McNaughton C,Osani M,Shmerling RH,Curtis JR,Furst DE,Parks D,Kavanaugh A,O'Dell J,King C,Leong A,Matteson EL,Schousboe JT,Drevlow B,Ginsberg S,Grober J,St Clair EW,Tindall E,Miller AS,McAlindon T, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care     [PubMed]
Thalayasingam N,Isaacs JD, Anti-TNF therapy. Best practice     [PubMed]
Rosenblum H,Amital H, Anti-TNF therapy: safety aspects of taking the risk. Autoimmunity reviews. 2011 Jul;     [PubMed]
Bae SC,Kim J,Choe JY,Park W,Lee SH,Park YB,Shim SC,Lee SS,Sung YK,Choi CB,Lee SR,Park H,Ahn Y, A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Annals of the rheumatic diseases. 2017 Jan;     [PubMed]
Matsuno H,Tomomitsu M,Hagino A,Shin S,Lee J,Song YW, Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Annals of the rheumatic diseases. 2018 Apr;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pediatrics-Medical Student. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pediatrics-Medical Student, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pediatrics-Medical Student, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pediatrics-Medical Student. When it is time for the Pediatrics-Medical Student board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pediatrics-Medical Student.